Bayer and haemophilia
Patient information
You can download the following files in PDF format :
Summary of Product Characteristics Prescribing Information Patient Information LeafletSince introducing our first Factor VIII (FVIII) concentrate in the early 1970's, we have dedicated ourselves to advancing the safety and efficacy of the factor VIII treatment we manufacture for patients with haemophilia A. We also strive to provide the bleeding disorders community with the tools, associated support programmes, and resources that can facilitate an improvement in the quality of life for those patients.
Information that can be found in this section:
What is haemophilia?Bayer's commitmentResearch and developmentHaemophilia awards programmePatient support
ClinicalTrials.gov
Find out about ongoing trials in haemophilia by visiting ClinicalTrials.gov
Bayer Haemophilia Awards
For more information about the programme click here